Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Fig. 3

Forest plot of CGRP mAb vs. placebo for the changes in baseline monthly acute migraine-specifc medication days. The estimated pooled WMD was − 1.28 (95% CI, − 1.66 to − 0.90) with high statistical significance (P < 0.00001). There was high heterogeneity among the studies (I2 = 77%). SD standard deviation, CI confidence interval, WMD weighted mean difference

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us